Serum anti-GAGA4 IgM antibodies differentiate relapsing remitting and secondary progressive multiple sclerosis from primary progressive multiple sclerosis and other neurological diseases.
J Brettschneider, TD Jaskowski, H Tumani, S Abdul, D Husebye, H Seraj, HR Hill, E Fire, L Spector, J Yarden , N Dotan and JW Rose
J Neuroimmunol 2009; 217;95-101

Anti-alpha-glucose based glycan IgM antibodies predict relapse Activity in Multiple Sclerosis after the first neurological event.
MS Freedman, J Laks, N Dotan, RT Altstock, A Dukler, and CJM Sindic
Mult Scler 2009; 15: 422-430.

Serum anti-Glc(alpha1,4)Glc(alpha) antibodies as a biomarker for relapsing-remitting multiple sclerosis.
M Schwarz , L Spector , M Gortler , O Weishaus , L Glass-Marmor , A Karni , N Dotan , A Miller
J Neurol Sci 2006;244:59-68.

Conference Abstracts

Oral / Platform Presentations

  
2010 AAN 62nd Annual Meeting:
Antibodies (gMS® Dx Test) Differentiate Newly Diagnosed Relapsing Remitting Multiple Sclerosis Patients from Other Inflammatory Demyelinating Disease Patients within One Year from Diagnosis.

2006 AUTOIMMUNITY 5th International Congress:
Prognosis in Multiple Sclerosis.
C Sindic. Abstracts of 5th international Congress on Autoimmunity, Autoimmunity Reviews.
2006; ISSN 1568-9972:p 203.

 

2006 ACTRMS 11th Annual Meeting:
Validation of anti-GAGA4 IgM antibodies for predicting the development of relapsing remitting MS after the first neurological event.
MS Freedman, J Laks, N Dotan, RT Altstock, A Dukler and C Sindic
Mult Scler  2007; 13: 278-230.

 

2005 ECTRIMS/ACTRIMS Joint Meeting:
Anti-Glc(alpha 1,4)Glc(alpha) IgM Antibodies for Predict the Development of Relapsing Remitting Multiple Sclerosis after the First Neurological Event.
MS Freedman, N Dotan, M Schwarz, O Weishaus, A Dukler, A Dukler, A Miller, and C Sindic
Mult Scler  2005; 11-S1: 180 P678.

 

2004 International Society of Neuroimmunology 7th International Congress:
The use of GlycoChip® microarray technology for identification of anti-Glc(alpha 1,4)Glc(alpha)-serum antibodies as specific biomarker for multiple sclerosis.
M. Schwarz, L Spector, M Gortler, L Glass-Marmor, A Karni, N Dotan and A Miller.
Journal of Neuroimmunol 2004; 154: P325. 

Poster Presentations

 

 

2009 ACTRIMS:

2009 ECTRIMS:
Anti-alpha-glucose based glycan IgM antibodies in patients with a clinically isolated syndrome:
analyses from the BEtaferon® in Newly Emerging multiple sclerosis For Initial Treatment (BENEFIT) study
M Freedman, G Edan, HP Hartung, L Kappos, D Miller, X Montalban, CH Polman, N Dotan, V Lanius,
C Metzig, S Schwenke, C Pohl, R Sandbrink for the BENEFIT Study Group
Mult Scler 2009; 15: S71.

2008 ACTRIMS/ECTRIMS/LACTRIMS Joint Meeting:
Performance of an anti-GAGA4 IgM assay in distinguishing multiple sclerosis patients from control groups in a US cohort: a cross sectional retrospective study
TD Jaskowski, D Husebye, HS Seraj, J Yarden, L Spector, E Fire, N Dotan, HR Hill, JW Rose
Mult Scler 2008; 14: S282.

 

A successful validation of the ability of anti-GAGA4 IgM antibody assay to differentiate multiple sclerosis patients from other neurological diseases patients in a German cohort: a cross-sectional retrospective analysis.
J Brettschneider, S Abdul, E Fire, J Yarden, L Spector, N Dotan, H Tumani
Mult Scler 2008; 14: S290.

 

2006 ECTRIMS 22nd Conference:
A panel of anti-glycan IgM antibodies for predicting the development of relapsing-remitting multiple sclerosis after the first neurological event.
MS Freedman, A Miller, M Schwarz, O Weishaus, RT Altstock, A Dukler, N Dotan, C Sindic
Mult Scler 2006; 12: S167.

 

2004 ECTRIMS 20th Conference:
Anti-Glc(alpha 1,4)Glc(alpha)-specific serum antibodies in patients with multiple sclerosis for use in disease management
M. Schwarz, L Spector, M Gortler, L Glass-Marmor, A Karni, N Dotan and A Miller.
Mult Scler 2004; 10:S97-283.